



ASX Release:

Date: 21 December 2006

CHANGE OF COMPANY NAME TO VIRALYTICS LTD

Psiron will today officially change its name to Viralytics Ltd to better reflect the Company's focus on its world leading Virotherapy Intellectual Property.

The new ASX code will be VLA. The ASX will advise the market of the date that this new code will become effective.

The Company's technology is based on the capacity of Viralytics stable of human enteroviruses to target and destroy cancer cells.

The Company has recently announced approval to commence its second human trial (a Phase I dose escalation intratumoural administration of CAVATAK™ in late stage Melanoma patients and lodgement of an additional Ethics Committee Submission for what is expected to be the Company's third human trial (a Phase I multi-dose intravenous administration of CAVATAK™ in late stage Breast, Prostate and Melanoma cancer patients)

The company has also recently released exciting pre-clinical research results in Breast, Prostate and Multiple Myeloma cancers. Details of this research are available on the Company's website

www.viralytics.com

The name change is the result of a resolution adopted at the Company's Annual General Meeting on the 23rd November 2006.

Bryan Dulhunty
Executive Chairman